Efficacy comparison of two neoadjuvant chemotherapy regimens in human epidermal growth factor receptor 2 positive breast cancer: a retrospective study

doi:10.3877/cma.j.issn.1674-0807.2023.02.004

Abstract

Abstract:

Objective

To compare the efficacy of the ACH-TH regimen (liposomal-encapsulated doxorubicin+ cyclophosphamide+ trastuzumab, followed by paclitaxel+ trastuzumab) and the TCH regimen (docetaxel + carboplatin + trastuzumab) for neoadjuvant chemotherapy of HER-2 positive breast cancer.

Methods

We retrospectively collected the clinical data of 36 HER-2 positive breast cancer patients who received neoadjuvant chemotherapy in four hospitals (Zhongda Hospital of Southeast University, Nanjing First Hospital, Jiangsu Provincial Hospital of Traditional Chinese Medicine and Jiangsu Provincial Cancer Hospital) from January 1, 2017 to January 31, 2020, including 17 cases in the ACH-TH group and 19 cases in the TCH group. The pathological complete response (pCR) rate and incidence of adverse reactions between the two groups were compared using Fisher’s exact test.

Results

The pCR rate was 13/17 in the ACH-TH group, which was significantly higher than that in the TCH group (4/19) (P=0.002). The incidences of bone marrow suppression and alopecia in the ACH-TH group were significantly lower than those in the TCH group (2/17 vs 10/19, P=0.014; 0 vs 19/19, P<0.001). However, there was no significant difference in the incidence of other adverse events such as cardiotoxicity, gastrointestinal reactions, oral mucosal reactions and hand-foot syndrome between the two groups (P=1.000, 1.000, 0.216, 0.487).

Conclusion

ACH-TH regimen is the optimal regimen for neoadjuvant chemotherapy of HER-2 positive breast cancer patients.

Key words: Breast neoplasms, Receptor, ErbB-2, Neoadjuvant therapy, Doxorubicin

Jianxin Lyu, Yueyun Zhu, Ya’nan Zhang, Haolin Hu, Baocai Wang, Xinhua Cao, Lifei Han, Xiao Ma. Efficacy comparison of two neoadjuvant chemotherapy regimens in human epidermal growth factor receptor 2 positive breast cancer: a retrospective study[J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(02): 88-92.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2023.02.004

https://zhrxbzz.cma-cmc.com.cn/EN/Y2023/V17/I02/88

Figures/Tables 2

References 27

[1]	Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021，149：778-789.
[2]	中国临床肿瘤学会指南工作委员会．中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2017.V1)[M]. 北京：人民卫生出版社，2017.
[3]	Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938)：164-172.
[4]	U．S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0[EB/OL]. [2021-10-17]. URL
[5]	Lambertini M, Pond NF, Solinas C, et al. Adjuvant trastuzumab: a 10-year overview of its benefit[J]. Expert Rev Anticancer Ther, 2017，17(1)：61-74.
[6]	Pomponio MK, Burkbauer L, Goldbach M, et al. Refining the indications for neoadjuvant chemotherapy for patients with HER-2+ breast cancer: A single institution experience[J]. J Surg Oncol, 2020，121(3)：447-455.
[7]	Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]．J Clin Oncol, 2013, 31(31)：3997-4013.
[8]	Demichele A, Yee D, Paoloni M, et al. Neoadjuvant as future for drug development in breast cancer: response[J]. Clin Cancer Res, 2016，22(1)：269-269.
[9]	中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]．中国癌症杂志，2017，27(9)：695-759.
[10]	Houssami N, Macaskill P, Minckwitz GV, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy[J]. Eur J Cancer, 2012，48(18)：3342-3354.
[11]	Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis[J]. J Natl Cancer Inst, 2005，97(3): 188-194.
[12]	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[13]	Simon PS. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications[J]. Ther Adv Med Oncol, 2014，6(5)：210-221.
[14]	廖宁，张国淳，李学瑞，等．联合曲妥珠单克隆抗体的新辅助化疗方案用于HER-2阳性乳腺癌的Meta分析[J]．南方医科大学学报，2009，29(5)：943-945.
[15]	Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 4. 2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018，15(3)：310-320.
[16]	中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志，2019，29(8)：609-680.
[17]	Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety[J]. Crit Rev Oncol Hematol, 2008，66(1)：31-41.
[18]	Untch M, Eidtmann H, Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial[J]. Eur J Cancer, 2004, 40(7)：988-997.
[19]	Hyams D, Leichman G, Klein P, et al. Phase II trial of neoadjuvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable HER-2-positive breast cancer[J]. Cancer Res, 2010，69(24 Suppl)：1098-1098.
[20]	Gavila J, Guerrero A, Climent MA, et al. Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice[J]. Int J Clin Oncol, 2015，20(3)：480-489.
[21]	Uriarte-Pinto M, Escolano-Pueyo A, Gimeno-Ballester V, et al. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer[J]. Int J Clin Pharm, 2016, 38(2)：446-453.
[22]	马腾，史亚飞，马天怡，等. AC-TH与TCH方案对HER-2过表达乳癌新辅助化疗效果比较[J]. 青岛大学学报：医学版，2021, 57(3)：365-368.
[23]	徐玲，叶京明，朱赛楠，等．HER-2阳性早期乳腺癌TCH方案新辅助治疗疗效分析[J]．中华医学杂志，2018，98(12)：907-911.
[24]	Echavarria I, Granja M, Bueno C, et al. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer[J]. Breast Cancer Res Treat, 2017，162(1)：181-189.
[25]	Baselga1 J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER-2-positive metastatic breast cancer[J]. Ann Oncol, 2014，25(3)：592-598.
[26]	Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma[J]. Cancer, 2002，94(1)：25-36.
[27]	Rivankar S. An overview of doxorubicin formulations in cancer therapy[J]. J Cancer Res Ther, 2014，10(4)：853-858.

组别	例数	年龄(岁)	TNM分期		腋窝淋巴结		激素受体		组织学分级
组别	例数	年龄(岁)	Ⅱ期	Ⅲ期	阴性	阳性	阴性	阳性	2级	3级
ACH-TH组	17^a	50.5±7.1	6	11	5	12	9	8	10	7
TCH组	19^a	51.7±8.7	9	10	2	17	4	15	13	6
检验值		t＝－0.394
P值		0.696	0.516^b		0.219^b		0.082^b		0.730^b

组别	例数	年龄(岁)	TNM分期		腋窝淋巴结		激素受体		组织学分级
组别	例数	年龄(岁)	Ⅱ期	Ⅲ期	阴性	阳性	阴性	阳性	2级	3级
ACH-TH组	17^a	50.5±7.1	6	11	5	12	9	8	10	7
TCH组	19^a	51.7±8.7	9	10	2	17	4	15	13	6
检验值		t＝－0.394
P值		0.696	0.516^b		0.219^b		0.082^b		0.730^b

组别	例数	骨髓抑制	心脏毒性	脱发	口腔黏膜炎	手足综合征	胃肠道反应
ACH-TH组	17^a	2	0	0	2	0	0
TCH组	19^a	10	1	19	0	2	1
P值		0.014^b	1.000^b	<0.001^b	0.216^b	0.487^b	1.000^b

组别	例数	骨髓抑制	心脏毒性	脱发	口腔黏膜炎	手足综合征	胃肠道反应
ACH-TH组	17^a	2	0	0	2	0	0
TCH组	19^a	10	1	19	0	2	1
P值		0.014^b	1.000^b	<0.001^b	0.216^b	0.487^b	1.000^b

Please choose a citation manager

Content to export